In September, the innovative drug sector was impacted by several pivotal events, suggesting a potential resurgence in growth. Following the realignment of funds within the technology sector, innovative drugs could emerge as a fresh focal point. Investors are advised to keep an eye on resources, innovative drugs, consumer electronics, and other pertinent fields. Notably, the innovative drug sector is propelled by both policy incentives and market dynamics, characterized by accelerated commercialization processes and heightened R&D investments, demonstrating robust developmental momentum.